Pfizer Licenses OPKO’s Long-Acting Human Growth Hormone
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 1 (Table of Contents)
Published: 8 Jan-2015
DOI: 10.3833/pdr.v2015.i1.2087 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In return for one of the largest upfront payments ever agreed for a Phase III licensing deal, Pfizer has obtained global rights to develop and commercialise hGH-CTP, OPKO Health’slong-acting human growth hormone(hGH) product for the treatment of conditions associated with growth hormone deficiency...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS